MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, CLRB has $11,119,761 in assets. $6,402,651 in debts. $8,347,090 in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
190.14%
Quick Ratio
190.14%
Cash Ratio
171.26%
Debt to Asset Ratio
57.58%
Unit: Dollar
Assets Breakdown
    • Cash and cash equivalents
    • Operating lease right-of-use ass...
    • Prepaid expenses and other curre...
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accounts payable and accrued lia...
    • Others

Balance Sheets
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Cash and cash equivalents
8,347,090 13,196,033 12,554,289 11,041,027
Prepaid expenses and other current assets
920,038 842,432 1,067,409 1,576,579
Total current assets
9,267,128 14,038,465 13,621,698 12,617,606
Property, plant & equipment, net
339,697 549,405 595,271 647,549
Operating lease right-of-use asset
1,483,156 360,671 380,841 400,248
Other long-term assets
29,780 29,780 29,780 29,780
Total assets
11,119,761 14,978,321 14,627,590 13,695,183
Lease liability, current
-100,189 96,034 92,022
Accounts payable and accrued liabilities
4,724,826 4,423,548 4,014,682 4,678,713
Warrant liability
149,000 226,000 801,650 1,095,926
Total current liabilities
4,873,826 4,749,737 4,912,366 5,866,661
Lease liability, net of current portion
1,528,825 309,397 335,895 361,487
Total liabilities
6,402,651 5,059,134 5,248,261 6,228,148
Series d preferred stock, 111.11 shares authorized, issued and outstanding as of march 31, 2026 and december 31, 2025
1,382,023 1,382,023 1,382,023 1,382,023
Series e-2 preferred stock, 1,225.00 shares authorized 35.60 and 35.60 shares issued and outstanding as of december 31, 2025 and 2024, respectively-Series E2Preferred Stock
-520,778 --
Series e-2 preferred stock, 1,225.00 shares authorized 35.60 shares issued and outstanding as of march 31, 2026 and december 31, 2025
520,778 -520,778 520,778
Common stock, 0.00001 par value 170,000,000 shares authorized 4,240,129 shares issued and outstanding as of march 31, 2026 and december 31, 2025
42 42 32 18
Additional paid-in capital
277,601,713 277,149,844 271,314,776 264,958,619
Accumulated deficit
-274,787,446 -269,133,500 -263,838,280 -259,394,403
Total stockholders' equity (deficit)
3,335,087 8,537,164 7,997,306 6,085,012
Total liabilities and stockholders' equity
11,119,761 14,978,321 14,627,590 13,695,183
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$8,347,090 Prepaid expenses andother current assets$920,038 Total current assets$9,267,128 Operating leaseright-of-use asset$1,483,156 Property, plant &equipment, net$339,697 Other long-termassets$29,780 Total assets$11,119,761 Total liabilities andstockholders' equity$11,119,761 Total liabilities$6,402,651 Total stockholders'equity (deficit)$3,335,087 Series d preferredstock, 111.11 shares...$1,382,023 Accumulated deficit-$274,787,446 Total currentliabilities$4,873,826 Lease liability, netof current portion$1,528,825 Additional paid-in capital$277,601,713 Series e-2 preferredstock, 1,225.00 shares...$520,778 Common stock, 0.00001par value...$42 Accounts payable andaccrued liabilities$4,724,826 Warrant liability$149,000

Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences, Inc. (CLRB)